The peptideresearchalliance comparison
A shared conversation can accommodate very different levels of evidence. Ranking the molecules from best to worst would miss the point.
The question each compound answered
The ipamorelin trial asks about a meal after surgery. The retatrutide obesity trial asks about body weight over 48 weeks. Bremelanotide’s trials concern desire and distress. Even with excellent data, these would remain different questions.
I’d give each compound an introduction that preserves its purpose. This table is a set of introductions, rather than a scorecard.
Five research records
| Compound | A finding worth discussing | Human record and status |
|---|---|---|
| Ipamorelin | Time to first tolerated meal failed the primary test | Published Phase 2 bowel-surgery trial and an acute hormone-response study; no drug approval. |
| Retatrutide | Substantial mean body-weight reduction | Multiple Phase 2 trials and ongoing Phase 3 development; investigational, without FDA approval. |
| BPC-157 | Vessel growth in cell and animal models | Small human pilots, with large controlled trials lacking; no FDA-approved indication. |
| PT-141 | Improvement in desire and desire-related distress | Phase 3 trials and an extension; approved for acquired, generalized HSDD in premenopausal women. |
| NAD+ | Oral precursor studies raised blood NAD+ | Human NMN and NR trials, limited clinical efficacy; coenzyme and supplement context, distinct from peptide drug approval. |
Agreement and replication
BPC-157’s concentrated preclinical literature raises a question that an alliance ought to take seriously: how often has another group challenged the same idea? A broad range of models can be useful while confirmation by unrelated teams remains limited.
Ipamorelin offers the complementary difficulty. There is a human efficacy test, and the primary outcome failed. I’d ask the next investigator to start with that recorded disappointment before adding another catalogue of mechanisms. It tells the next investigator where confidence ran ahead of a demonstrated clinical result.
PT-141’s desire and distress results and the hamster reward experiment also resist an easy agreement. Their populations and endpoints differ, so they can coexist without either paper cancelling the other.
Regulatory differences
BPC-157’s withdrawn nomination on FDA’s page current as of April 22, 2026 retains safety concerns and does not establish permission to compound. Ipamorelin acetate has a withdrawn 503A nomination and remains in Category 2 under 503B. BPC-157 and ipamorelin are prohibited in sport at all times under WADA’s S0 and S2 categories respectively.
For PT-141, the approved indication and contraindications govern the claim: acquired, generalized HSDD in premenopausal women, with uncontrolled hypertension and known cardiovascular disease excluded. Retatrutide remains investigational. NAD+ precursor studies answer questions in a supplement context; compounded injectable preparations introduce different quality concerns.
I see an alliance of questions here, with separate verdicts. Their common audience gives them a place in one discussion. Each compound still has to bring its own result.